Insmed presents new data across three pillars at american thoracic society 2022 international conference

—retrospective cohort study shows significant reductions in all-cause and respiratory disease-related hospitalizations in the 12 months following arikayce® (amikacin liposome inhalation suspension) initiation in real-world settings— —post-hoc analysis of phase 2 willow study in adult patients with non-cystic fibrosis bronchiectasis supports favorable benefit-risk profile of brensocatib— bridgewater, n.j. , may 17, 2022 /prnewswire/ -- insmed incorporated (nasdaq:insm), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today reported data from seven presentations across three of its pillars—arikayce, brensocatib, and treprostinil palmitil inhalation powder (tpip)—at the american thoracic society (ats) 2022 international conference.
INSM Ratings Summary
INSM Quant Ranking